Nausea, diarrhea, decreased appetite, vomiting, and constipation occur in a dose-dependent manner, with higher rates at maximum doses, and typically diminish in severity as treatment continues
In contrast, NOS inhibition during withdrawal largely seems to be beneficial
Most UnitedHealthcare plans require BMI thresholds, evidence of weight-related conditions, lifestyle program participation, and proof of progress (often 5% weight loss) for continued coverage
There are many ways to design studies to test this, but the core of the question is whether GLP-1s are able to dramatically expand the number of patients that will accept treatment
longer-term recovery during intense training cycles and why your protocol shouldnt look the same in every situation